Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Drug Resistance, Neoplasm
Contrast enhanced MRI does not adequately assess disease status during bevacizumab therapy for recurrent glioblastoma (GBM). A nonenhancing tumor pattern of progression is common after treatment with bevacizumab for GBM and is correlated with worse survival. Treatments after bevacizumab failure provide only transient tumor control.